Interactive clinical discussion on XPOVIO
XPOVIO (selinexor): Now approved as early as 1st relapse in multiple myeloma BY: Rajesh Behl, MD Alta Bates Summit Comprehensive Cancer Center
RSVP: https://www.karyopharmevents.com/8xS9F4 866-914-9069 / VDE_KaryopharmRSVP@veeva.com 602-770-6148 / drobson@karyopharm.com KAR0001372 Please reference this number during registration. |
|